Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 16753 

The parties entered into a Voluntary 

Settlement Agreement (Agreement) to 

conclude this matter without further 

expenditure of time, finances, or other 

resources. The settlement is not an 

admission of liability on the part of the 

Respondent. 

Respondent voluntarily agreed to the 

following: 

(1) Respondent will have his research 

supervised for a period of twelve (12) 

years beginning on March 1, 2022 (the 

‘‘Supervision Period’’). Prior to the 

submission of an application for PHS 

support for a research project on which 

Respondent’s participation is proposed 

and prior to Respondent’s participation 

in any capacity in PHS-supported 

research, Respondent will submit a plan 

for supervision of Respondent’s duties 

to ORI for approval. The supervision 

plan must be designed to ensure the 

integrity of Respondent’s research. 

Respondent will not participate in any 

PHS-supported research until such a 

supervision plan is approved by ORI. 

Respondent will comply with the 

agreed-upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2–3 senior faculty 

members at the institution who are 

familiar with Respondent’s field of 

research, but not including 

Respondent’s supervisor or 

collaborators, will provide oversight and 

guidance. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 

intervals setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved. The review will include a 

discussion with Respondent of the 

primary data represented in those 

documents and will include a 

certification to ORI that the data 

presented in the proposed application, 

report, manuscript, or abstract is 

supported by the research record. 

(3) During the Supervision Period, 

Respondent will ensure that any 

institution employing him submits, in 

conjunction with each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract. 

(4) If no supervision plan is provided 

to ORI, Respondent will provide 

certification to ORI at the conclusion of 

the Supervision Period that his 

participation was not proposed on a 

research project for which an 

application for PHS support was 

submitted and that he has not 

participated in any capacity in PHSsupported research. 

(5) During the Supervision Period, 

Respondent will exclude himself 

voluntarily from serving in any advisory 

or consultant capacity to PHS including, 

but not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee. 

Dated: March 21, 2022. 

Wanda K. Jones, 

Acting Director, Office of Research Integrity, 

Office of the Assistant Secretary for Health. 

[FR Doc. 2022–06247 Filed 3–23–22; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier: OS–0990–New] 

Agency Information Collection 

Request. 60-Day Public Comment 

Request 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before May 23, 2022. 

ADDRESSES: Submit your comments to 

Sherrette.Funn@hhs.gov or by calling 

(202) 795–7714. 

FOR FURTHER INFORMATION CONTACT: 

When submitting comments or 

requesting information, please include 

the document identifier 0990–New–60D 

and project title for reference, to 

Sherrette A. Funn, email: 

Sherrette.Funn@hhs.gov, or call (202) 

795–7714 the Reports Clearance Officer. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collection: Health Care 

Readiness Collections. 

Type of Collection: Revision. 

OMB No.: 0990–0391. 

Abstract: The Office of the Assistant 

Secretary for Preparedness and 

Response (ASPR) in the Department of 

Health and Human Services (HHS) 

administers a portfolio of health care 

readiness programs and activities, 

including the Hospital Preparedness 

Program (HPP) authorized under 

Section 319C–2 of the Public Health 

Service (PHS) Act. HPP is a cooperative 

agreement program that strengthens 

national health care readiness, supports 

health care resilience, and enables rapid 

recovery. 

Through the Health Care Readiness 

Portfolio, ASPR provides awards to 62 

health departments in all 50 states, 

territories, freely associated states, and 

four metropolitan areas to support the 

health care delivery system through 

over 320 health care coalitions (HCCs) 

with nearly 45,000 members. An HCC is 

a network of public and private 

organizations that partner to conduct 

planning, training, and preparedness 

activities within a state or locality, 

building that area’s overall readiness. 

ASPR’s Health Care Readiness 

Portfolio aligns preparedness activities 

across health care and also includes the 

Regional Disaster Health Response 

System (RDHRS) demonstration sites 

that establish regional partnerships to 

develop promising practices in 

coordinating disaster readiness and 

regional medical response; the National 

Special Pathogen System, a nationwide 

systems-based network approach for 

special pathogen care; workforce 

capacity activities; and other initiatives. 

ASPR collects data annually to 

understand how federal funding has 

been spent, measure performance, and 

monitor adherence with program 

requirements. These data additionally 

support ASPR to develop funding 

opportunities, improve programmatic 

operations, and inform decision-making. 

ASPR is also responsible for allocating 

and monitoring emergency and 

supplemental funding, understanding 

recipient and sub-recipient real-time 

needs, and maintaining situational 

awareness of the current state of 

preparedness, response, and recovery 

activities. When circumstances require 

rapid information gathering, it is 

necessary for ASPR to also collect data 


khammond on DSKJM1Z7X2PROD with NOTICES
16754 Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 

on an ad hoc basis to advance these 

goals. ASPR is changing the title of this 

collection from ‘‘Hospital Preparedness 

Program Data Collection’’ to ‘‘Health 

Care Readiness Collections’’ to better 

reflect the scope of data collected under 

this approval. 

ANNUALIZED BURDEN HOUR TABLE

Forms 

(If necessary) 

Respondents 

(If necessary) 

Number of 

respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total burden 

hours 

HPP Recipient End-of-Year Performance Report Collection.HPP Recipients ................................ 62 1 21 1,302 

HPP Sub-Recipient End-of-Year Performance Report Collection.HPP Sub-Recipients ........................ 321 1 4 1,284 

Ad hoc Information Collections ......... ASPR Health Care Readiness Portfolio Stakeholders.5,296 1 1 5,296 

Total ........................................... ........................................................... ........................ 3 ........................ 7,882 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2022–06255 Filed 3–23–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against 

Daniel Leong, Ph.D. (Respondent), 

formerly a Research Technician, Albert 

Einstein College of Medicine (AECM). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases (NIAMS), National Institutes of 

Health (NIH), grant R01 AR050968 and 

National Heart, Lung, and Blood 

Institute (NHLBI), NIH, grant P01 

HL110900. The administrative actions, 

including debarment for a period of four 

(4) years followed by supervision for a 

period of four (4) years, were 

implemented beginning on February 28, 

2022, and are detailed below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H., Acting 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 240, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Daniel Leong, Ph.D., Albert Einstein 

College of Medicine: Based on the report 

of an investigation conducted by AECM 

and analysis conducted by ORI in its 

oversight review, ORI found that Dr. 

Daniel Leong, formerly a Research 

Technician, AECM, engaged in research 

misconduct in research supported by 

PHS funds, specifically NIAMS, NIH, 

grant R01 AR050968 and NHLBI, NIH, 

grant P01 HL110900. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, or recklessly falsifying and/ 

or fabricating data included in sixteen 

(16) grant applications submitted for 

PHS funds: 

• R01 AR065563–01, ‘‘CITED2 and 

Chondroprotection,’’ submitted to 

NIAMS, NIH, on 02/05/2013. 

• R01 AR066009–01, ‘‘Remote 

Loading for Osteoarthritis,’’ submitted 

to NIAMS, NIH, on 06/04/2013. 

• R01 AR065563–01A1, ‘‘CITED2 and 

Chondroprotection,’’ submitted to 

NIAMS, NIH, on 11/05/2014. 

• R41 AR070695–01, ‘‘A novel 

product for tendinopathy treatment,’’ 

submitted to NIAMS, NIH, on 01/05/ 

2015. 

• R01 AG069693–01, ‘‘Chondrocyte 

fate regulation and cartilage protection,’’ 

submitted to National Institute on Aging 

(NIA), NIH, on 06/05/2015. 

• R01 AG039561–06, ‘‘Human tendon 

stem progenitor cell aging and 

regeneration,’’ submitted to NIA, NIH, 

on 03/15/2016 (original grant funding 

from 08/15/2012–04/30/2018). 

• R43 AT009414–01, ‘‘A novel 

nutraceutical drug for tendinopathy 

treatment,’’ submitted to National 

Center for Complementary and 

Alternative Medicine (NCCAM), NIH, 

on 04/05/2016. 

• R01 AR070431–01A1, ‘‘The role of 

Panx1 in the pathogenesis and pain of 

osteoarthritis,’’ submitted to NIAMS, 

NIH, on 07/19/2016. 

• R41 AG056246–01A1, ‘‘A novel 

product for tendinopathy treatment,’’ 

submitted to NIA, NIH, on 09/06/2016, 

funded from 09/15/2017–08/31/2019. 

• R01 AG056623–01, ‘‘Chondrocyte 

fate regulation and osteoarthritis,’’ 

submitted to NIA, NIH, on 10/05/2016. 

• R01 AR072038–01, ‘‘MSC-derived 

exosomes and tendon disorders,’’ 

submitted to NIAMS, NIH, on 10/05/ 

2016. 

• R43 AT009414–01A1, ‘‘A novel 

nutraceutical drug for tendinopathy 

treatment,’’ submitted to NCCAM, NIH, 

on 04/05/2017, funded from 08/01/ 

2018–07/31/2020. 

• R01 AR073194–01, ‘‘Chondrocyte 

fate regulation and cartilage protection,’’ 

submitted to NIAMS, NIH, on 06/05/ 

2017. 

• R01 AR074802–01, ‘‘The role of 

Panx1 in the pathogenesis and pain of 

osteoarthritis,’’ submitted to NIAMS, 

NIH, on 04/02/2018. 

• R01 AR074802–01A1, ‘‘The role of 

Panx1 in the pathogenesis and pain of 

osteoarthritis,’’ submitted to NIAMS, 

NIH, on 08/01/2018. 

• R44 AG065089–01, ‘‘Botanical drug 

for spontaneous osteoarthritis,’’ 

submitted to NIA, NIH, on 01/07/2019. 

ORI found that Respondent 

intentionally, knowingly, or recklessly 

falsified and/or fabricated Western blot 

and histological image data for chronic 

deep tissue conditions including 

osteoarthritis (OA) and tendinopathy in 

murine models by reusing image data, 

with or without manipulating them to 

conceal their similarities, and falsely 

relabeling them as data representing 

different experiments in fifty (50) 

figures included in sixteen (16) PHS 

grant applications. In the absence of 

reliable image data, the figures, 

quantitative data in associated graphs 

purportedly derived from those images, 

statistical analyses, and related text also 

are false. 

Specifically, ORI found that: 

1. Respondent reused and relabeled 

Western blot images from the same 

source to falsely represent different 

proteins and/or experimental results in: 


khammond on DSKJM1Z7X2PROD with NOTICES